Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.

about

A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633).Efficacy of levomilnacipran extended release in treating major depressive disorder.

P2860

Q38770060-36557763-D67E-4145-982B-257F8AE3FB13 Q47303967-5D02FD12-4923-44BB-B2A7-60F29552A800

P2860

Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.

Item

http://www.wikidata.org/entity/Q35794456

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Disposition and metabolism of ...... in humans, monkeys, and rats.

@ast

Disposition and metabolism of ...... in humans, monkeys, and rats.

@en

type

Item

label

Disposition and metabolism of ...... in humans, monkeys, and rats.

@ast

Disposition and metabolism of ...... in humans, monkeys, and rats.

@en

prefLabel

Disposition and metabolism of ...... in humans, monkeys, and rats.

@ast

Disposition and metabolism of ...... in humans, monkeys, and rats.

@en

P1476

Disposition and metabolism of ...... in humans, monkeys, and rats.

@en

P2093

Bernadette Maynadier

http://www.w3.org/2001/XMLSchema#string

Isabelle Hude

http://www.w3.org/2001/XMLSchema#string

Laishun Chen

http://www.w3.org/2001/XMLSchema#string

Laurence Barthe

http://www.w3.org/2001/XMLSchema#string

Louise Roques

http://www.w3.org/2001/XMLSchema#string

Philippe Hermann

http://www.w3.org/2001/XMLSchema#string

Sébastien Séguier

http://www.w3.org/2001/XMLSchema#string

Valérie Brunner

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder

Cross-national epidemiology of DSM-IV major depressive episode.

Pharmacokinetics of milnacipran in liver impairment.

Which bioequivalence study for a racemic drug? Application to milnacipran.

Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.

The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI)

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

P304

3199-3215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S80886

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26150694

http://www.w3.org/2001/XMLSchema#string

P921

norepinephrine

P932

4484650

http://www.w3.org/2001/XMLSchema#string

Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.

about

P2860

P2860

Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932